STRO
Another AACR cameo
Sutro Biopharma rolled into the AACR Annual Meeting 2026 with preclinical data for two antibody-drug conjugates, and the market got the memo. The company said STRO-004 showed antitumor activity across multiple tissue factor-expressing solid tumor models, including disease control and tumor reduction at 5 mg/kg.
Why investors care
This is the part where biotech investors lean in. Pipeline data is basically the company’s bragging rights deck, and when the science looks alive, the stock can catch a bid. Sutro’s shares were trading near their 52-week high, which tells you the market is treating this like more than a science fair poster.
The second act: STRO-006
Sutro also shared data on STRO-006, its integrin β6-targeting ADC, which showed dose-dependent antitumor activity in solid tumor models, including non-small cell lung cancer and head and neck cancers.
- STRO-004: further along, with Phase 1 initial results expected in mid-2026
- STRO-006: still earlier, with an IND filing planned for 2026
The biotech math
Preclinical data doesn’t pay the bills by itself — this isn’t a checkout-line impulse buy. But for a biotech, strong early signals can improve the odds of financing, partnering, and surviving long enough to get to the really juicy human data.
Big picture: Sutro just gave the bulls another reason to keep swiping right on the pipeline story, even if the real relationship test is still ahead.